Sustainable KLH Technologies for Growing Markets

INVESTORS

Subscribe to RSS

  Receive Updates

Sedar Edgar

NEWS RELEASES

Apr 10, 2014
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (otcqb:SBOTF) CA:KLH -0.56% , a leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating prot...
Apr 4, 2014
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH), the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), will host a general corpora...
Apr 1, 2014
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH), announced that the company is presenting today at the 2014 TSX Venture 50® Spotlight Event being held in Calg...
Mar 3, 2014
Stellar Biotechnologies, Inc. ("Stellar" or the "Company") (OTCQB: SBOTF) (TSX-V: KLH) today announced the presentation of a poster at the Gordon Research Conference (GRC) on Marine Natural Product...
Feb 27, 2014
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH),) a company focused in the immunotherapy arena with world-leading technology in Keyhole Limpet Hemocyanin (KLH...
Feb 18, 2014
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH), announces that the Company held its Annual General and Special Meeting of Shareholders (the "Meeting") on Thu...
Feb 13, 2014
Stellar Biotechnologies, Inc. ("Stellar" or “the Company”) (OTCQB: SBOTF) (TSX-V: KLH), announced today that the Company has been named to the 2014 TSX Venture 50®, an exclusive ranking of the top ...
Feb 12, 2014
Stellar Biotechnologies, Inc. ("Stellar" or “the Company”) (OTCQB: SBOTF) (TSX-V: KLH), announced today the presentation of a poster at Aquaculture America 2014 (Seattle, February 9-12, 2014), desc...
Jan 6, 2014
Stellar Biotechnologies, Inc. ("Stellar" or “the Company”) (OTCQB: SBOTF) (TSX-V: KLH),) announced today that the Company will present at two upcoming investor conferences in January: the Biotech S...
Jan 2, 2014
Stellar Biotechnologies, Inc. ("Stellar" or “the Company”) (OTCQB: SBOTF) (TSX-V: KLH), announced today the filing of its annual report for the fiscal year ended August 31, 2013 and financial resul...
Dec 27, 2013
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH),) announced today that it will hold an annual general and special meeting of shareholders (the "Meeting") on F...
Dec 12, 2013
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH), announced today that it has entered into a collaboration agreement with Amaran Biotechnology, Inc., a private...
Dec 9, 2013
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH), the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), announced today the issuanc...
Dec 3, 2013
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH), the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), will host a general corpora...
Nov 25, 2013
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH), the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), announced today that the Comp...
Nov 20, 2013
Stellar Biotechnologies, Inc. ("Stellar" or “the Company”) (OTCQB: SBOTF) (TSX-V: KLH), announced today the appointment of Mark A. McPartland as Vice President of Corporate Development and Communic...
Nov 5, 2013
Stellar Biotechnologies, Inc. ("Stellar" or “the Company”) (OTCQB: SBOTF) (TSX-V: KLH), announced today the appointment of two of the Company’s senior executives to expanded leadership positions. ...
Oct 28, 2013
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH), announced today the presentation of a preclinical poster at the 7th Vaccine and ISV Congress being held in Si...
Oct 21, 2013
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH), announced today presentation of positive results from a preclinical study of the Company's KLH-conjugate acti...
Sep 25, 2013
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH), is very pleased to announce the appointment of Tessie Mary Che, Ph.D. to the Company’s Board of Directors.
Sep 23, 2013
Stellar Biotechnologies, Inc. ("Stellar" or “the Company”) (OTCQB: SBOTF) (TSX-V: KLH), announced today, further to its news releases of August 22, 2013 and September 10, 2013, the closing of its p...
Sep 10, 2013
Stellar Biotechnologies, Inc. ("Stellar" or “the Company”) (OTCQB: SBOTF) (TSX-V: KLH), announced today that, further to its news release of August 22, 2013, it has completed the initial closing of...
Aug 29, 2013
Stellar Biotechnologies, Inc. ("Stellar" or “the Company”) (OTCQB: SBOTF) (TSX-V: KLH), announced today that it will present at the Rodman and Renshaw 2013 Annual Global Investment Conference in Ne...
Aug 22, 2013
Stellar Biotechnologies, Inc. ("Stellar" or “the Company”) (OTCQB: SBOTF) (TSX-V: KLH), announces its intent to close a private placement of up to 11,428,572 units (the "Units") to raise gross proc...
Aug 6, 2013
Stellar Biotechnologies, Inc. ("Stellar" or “the Company”) (OTCQB: SBOTF) (TSX-V: KLH), is pleased to announce that it has issued a letter from Stellar President and CEO Frank Oakes, to update shar...
Jul 30, 2013
Stellar Biotechnologies, Inc. ("Stellar" or “the Company”) (OTCQB: SBOTF) (TSX-V: KLH), announced today that the Company has acquired the exclusive, worldwide license to patented technology for the...
Jul 24, 2013
Stellar Biotechnologies, Inc. ("Stellar" or “the Company”) (OTCQB: SBOTF) (TSX-V: KLH), announced today that a preclinical abstract on KLH-conjugate vaccine for Clostridium difficile infection (“C....
Jul 17, 2013
Stellar Biotechnologies, Inc. ("Stellar" or “the Company”) (OTCQB: SBOTF) (TSX-V: KLH), is very pleased to announce the appointment of Kathi Niffenegger, CPA, to the position of Corporate Secretary...
Jun 21, 2013
Stellar Biotechnologies, Inc. (“Stellar” or the “Company”) (OTCQB: SBOTF) (TSX-V: KLH) announces that Darrell Brookstein has resigned from his role as Executive VP, Corporate Development and Financ...
May 28, 2013
Stellar Biotechnologies, Inc. (“Stellar” or the “Company”) (OTCQB: SBOTF) (TSX-V: KLH) today announced the presentation of a poster at the Annual 2013 National Science Foundation (NSF) Conference i...
May 21, 2013
Stellar Biotechnologies, Inc. (SBOTF: OTCQB) (KLH: TSX-V) announced today that Frank Oakes, President & CEO and Darrell Brookstein, Executive VP, will present at the Second Annual Marcum LLP MicroC...
Apr 30, 2013
Stellar Biotechnologies, Inc. ("Stellar" or “the Company”) (OTCQB: SBOTF) (TSX-V: KLH), the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), today announced publication o...
Mar 19, 2013
Stellar Biotechnologies, Inc. ("Stellar" or “the Company”) (OTCQB: SBOTF) (TSX-V: KLH), the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), today announced the Company h...
Mar 13, 2013
Stellar Biotechnologies, Inc. ("Stellar" or “the Company”) (OTCQB: SBOTF) (TSX-V: KLH) today announced the presentation of results from a preclinical study of Keyhole Limpet Hemocyanin (KLH), condu...
Feb 19, 2013
Stellar Biotechnologies, Inc. ("Stellar" or “the Company”) (OTCQB: SBOTF) (TSX-V: KLH) today announced that the Company exceeded its 2012 plan to increase key stages of its aquaculture capacity to ...
Feb 6, 2013
Stellar Biotechnologies, Inc. ("Stellar" or “the Company”) (OTCQB: SBOTF) (TSX-V: KLH) today announced that the Company has submitted a provisional application for a patent to the U.S. Patent and T...
Jan 22, 2013
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced that the Company has successfully achieved a commercial-scale aquaculture system that su...
Jan 17, 2013
Stellar Biotechnologies, Inc. (“Stellar” or the “Company”) (OTCQB: SBOTF) (TSX-V: KLH), the world leader in sustainable manufacture of GMP-grade Keyhole Limpet Hemocyanin (KLH), today announced tha...
Jan 15, 2013
Stellar Biotechnologies, Inc. (“Stellar” or the “Company”) (OTCQB: SBOTF) (TSX-V: KLH), the world leader in sustainable manufacture of GMP-grade Keyhole Limpet Hemocyanin (KLH), is very pleased to ...
Jan 2, 2013
Stellar Biotechnologies, Inc. (“Stellar” or the “Company”) (TSX-V: KLH) (PINKSHEETS: SBOTF) (Frankfurt: RBT), the world leader in sustainable manufacture of GMP-grade Keyhole Limpet Hemocyanin (KLH...
Dec 12, 2012
Stellar Biotechnologies, Inc. (“Stellar” or the “Company”) (TSX-V: KLH) (PINKSHEETS: SBOTF) (Frankfurt: RBT), the world leader in sustainable manufacture of GMP-grade Keyhole Limpet Hemocyanin (KLH...
Nov 27, 2012
Stellar Biotechnologies, Inc. (“Stellar” or the “Company”) (TSX-V: KLH) (PINKSHEETS: SBOTF) (Frankfurt: RBT), the world leader in sustainable manufacture of GMP-grade Keyhole Limpet Hemocyanin (KLH...
Oct 31, 2012
Stellar Biotechnologies, Inc. (“Stellar” or the “Company”) (TSX-V: KLH) (PINKSHEETS: SBOTF) (Frankfurt: RBT), the world leader in sustainable manufacture of GMP-grade Keyhole Limpet Hemocyanin (KLH...
Oct 23, 2012
Stellar Biotechnologies, Inc. (“Stellar” or the “Company”) (TSX-V: KLH) (PINKSHEETS: SBOTF) (Frankfurt: RBT), the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), today a...
Oct 4, 2012
Stellar Biotechnologies, Inc. (“Stellar” or the “Company”) (TSX-V: KLH) (PINKSHEETS: SBOTF) (Frankfurt: RBT) is very pleased to announce the filing of a US Letters Patent Application directed to pr...
Sep 26, 2012
Stellar Biotechnologies, Inc. ("Stellar") (TSX-V: KLH) (PINKSHEETS: SBOTF) (Frankfurt: RBT) today announced that Frank Oakes, President and Chief Executive Officer of Stellar, presented at the 2nd ...
Aug 9, 2012
Stellar Biotechnologies, Inc. ("Stellar") (TSX-V: KLH) (PINKSHEETS: SBOTF) (Frankfurt: RBT) is very pleased to announce that Herbert S. Chow, Ph.D. has been appointed to the position of Chief Techn...
Jun 25, 2012
Stellar Biotechnologies, Inc. ("Stellar") (TSX-V: KLH) (PINKSHEETS: SBOTF) (Frankfurt: RBT) is pleased to report that an abstract prepared by Stellar scientists on KLH immunobiology has been accept...
Jun 20, 2012
Stellar Biotechnologies, Inc. ("Stellar") (TSX-V: KLH) (PINKSHEETS: SBOTF) (Frankfurt: RBT) is pleased to announced that Stellar scientists will be presenting new KLH science at the ICAAC 2012 Conf...
Apr 25, 2012
Stellar Biotechnologies, Inc. ("Stellar") (TSX-V: KLH) (PINKSHEETS: SBOTF) (Frankfurt: RBT) announced today the launch of KLH Site™ at www.klhsite.com, the first website dedicated to scientific and...
Apr 10, 2012
Stellar Biotechnologies, Inc. ("Stellar") (TSX-V: KLH) (U.S. PINKSHEETS: SBOTF) (Frankfurt: RBT) today announced that it has entered into an agreement with the University of Guelph (Ontario, Canada...
Apr 3, 2012
Stellar Biotechnologies, Inc. ("Stellar") (TSX-V: KLH) (U.S. OTC: SBOTF) (Frankfort: RBT), the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), announced today the launch...
Mar 13, 2012
Stellar Biotechnologies, Inc. ("Stellar") (TSX-V: KLH) (U.S. OTC: SBOTF) (Frankfort: RBT) announced today that the Company has published an update to its corporate profile brochure.
Jan 4, 2012
Stellar Biotechnologies, Inc. ("Stellar") (TSX-V: KLH) (U.S. OTC: SBOTF) is pleased to announce that it will be making two presentations at the Biotech Showcase 2012 Conference in San Francisco Jan...
Dec 20, 2011
Stellar Biotechnologies, Inc. (TSX-V: KLH) (U.S. OTC: SBOTF) ("Stellar" or the "Company") is pleased to announce that it has adopted a shareholder rights plan (the "Rights Plan") designed to encour...
Dec 6, 2011
Stellar Biotechnologies, Inc. ("Stellar") (TSX-V: KLH) (U.S. OTC: SBOTF) is pleased to announce the completion of a major expansion of its keyhole limpet (megathura crenulata) hatchery facility in ...
Nov 22, 2011
PORT HUENEME, CA--(Marketwire - November 22, 2011) - Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (PINKSHEETS: SBOTF) is pleased to report two recent news stories on the company, by the Nat...
Nov 2, 2011
Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (U.S. OTC: SBOTF) is pleased to announce they have retained A.B. Korelin & Associates Inc. of Blaine, WA to assist the Company in its preparatio...
Oct 26, 2011
Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (U.S. OTC: SBOTF) and Life Diagnostics, Inc. are pleased to announce they have entered into an exclusive manufacturing and supply agreement. Lif...
Sep 20, 2011
Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (U.S. OTC: SBOTF) is pleased to announce they have received the first purchase order from Sigma-Aldrich under terms of the marketing agreement b...
Sep 12, 2011
Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (U.S. OTC: SBOTF) is pleased to announce they have entered into an agreement for strategic business planning advisory services with LifeTech C...
Aug 29, 2011
PORT HUENEME, CA-- August 29, 2011 - Stellar Biotechnologies, Inc. "Stellar" (TSX-V:KLH) (U.S. OTC: SBOTF) is pleased to announce that the National Science Foundation (NSF) has granted Stellar a Ph...
Aug 3, 2011
PORT HUENEME, CA (August 3, 2011) -- Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (U.S. OTC: SBOTF) is pleased to announce they have entered into an agreement for marketing and sales with...
Jul 6, 2011
Stellar Biotechnologies, Inc. “Stellar” (TSX-V: KLH) (U.S. OTC: SBOTF) is pleased to announce that its President, Frank Oakes and Executive VP, Corporate Development & Finance, Darrell Brookstein r...
Jun 13, 2011
Stellar Biotechnologies, Inc. “Stellar” (TSX-V: KLH) (U.S. OTC: SBOTF) is pleased to announce that its semi-annual CEO Letter to Shareholders has been released.
May 24, 2011
Stellar Biotechnologies, Inc. (TSX-V: KLH) (U.S. OTC: SBOTF) is very pleased to announce that it has appointed David L. Hill, Ph.D. as a member of its board of directors.
May 10, 2011
Stellar Biotechnologies, Inc. (PINKSHEETS: SBOTF) (TSX-V: KLH) announces the completion of a pre-Investigational Device Exemption (pre-IDE) meeting with the U.S. Food and Drug Administration’s
Mar 8, 2011
Stellar Biotechnologies, Inc. (PINKSHEETS: SBOTF) (TSX-V: KLH) has appointed Michael R. McClurg to VP, Business Development & Marketing. His employment begins shortly, and Company Executive VP,...
Jan 25, 2011
Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) is pleased to announce successful completion of preclinical toxicity and immunogenicity testing of Stellar IMG KLH and Stellar Sub...
Dec 14, 2010
Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) is pleased to announce that its U.S. subsidiary has been awarded a $99,000 grant from The National Science Foundation (NSF)
Dec 7, 2010
Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) is pleased to announce that it has acquired an exclusive, irrevocable, worldwide, sub-licensable and royalty-free license to the techn...
Nov 30, 2010
Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) (www.StellarBiotechnologies.com) announces completion of preclinical toxicity and immunogenicity testing of Stellar KLH/SUBUNIT and St...
Nov 15, 2010
Stellar Biotechnologies, Inc. (the "Company" or “Stellar”) (TSX-V: KLH) (PINKSHEETS: SBOTF) is pleased to announce that it has closed the non-brokered private placement announced on October 25, 201...
Nov 4, 2010
Stellar Biotechnologies, Inc. (the "Company" or “Stellar”, TSX.V: KLH - U.S. OTC: SBOTF) is pleased to announce that its California subsidiary received news this week that it has been awarded two g...
Oct 25, 2010
Stellar Biotechnologies, Inc. (the "Company" or “Stellar”, TSX.V: KLH) announces a non-brokered private placement financing consisting of up to 6,000,000 units (the “Units”) at a purchase price of ...
Oct 20, 2010
Stellar Biotechnologies, Inc. announced today that its California subsidiary has been invited to submit a formal application for funding under the National Science Foundation’s (NSF) Technology Enh...
Oct 13, 2010
Stellar Biotechnologies, Inc. (“Stellar” or “the Company”) has been advancing on several fronts over their first quarter as a public company, and expects to achieve new milestones before year end. ...
Sep 30, 2010
Stellar Biotechnologies, Inc. received payment of US$ 288,000 for a filled order of Stellar KLH/SUBUNIT from French biotechnology and active immunotherapy technology-platform company
Sep 29, 2010
Stellar Biotechnologies, Inc. (Stellar) is pleased to announce that it has agreed to complete a CDN$ 1.05M private placement subject to acceptance by the TSX Venture Exchange
Sep 13, 2010
Stellar Biotechnologies, Inc. is collaborating with Bayer Innovation GmbH (BIG) in the development of biopharmaceuticals.
Sep 9, 2010
Stellar Biotechnologies, Inc. (PINK SHEETS: SBOTF & TSX-V: KLH) announces filing for patent protection of inventions related to its native Immunogenic (IMG) KLH technology platform and immune statu...
Jul 12, 2010
Stellar Biotechnologies, Inc. is pleased to announce that eminent biochemist, Malcolm Gefter, Ph. D. has accepted appointment to both Stellar's Board of Directors and to its Scientific Advisory Boa...
Jun 29, 2010
Stellar Biotechnologies, Inc. (OTC: SBOTF - TSX-V: KLH) has appointed John S. Sundsmo, Ph.D., VP - Research & Intellectual Property Management and Daniel C. Adelman, M.D. as a member of the Scienti...
Jun 22, 2010
Stellar Biotechnologies, Inc. (OTC: SBOTF - TSX-V: KLH) is pleased to announce that it has released its new customer and investor-friendly website at www.StellarBiotechnologies.com.
Jun 10, 2010
Stellar Biotechnologies, Inc. (OTC: SBOTF - TSX-V: KLH) will initiate preclinical testing of its immunogenic agent, Stellar KLH/NeoA, in anticipation of filing an IND application for its Stellar KL...
Jun 1, 2010
Stellar Biotechnologies, Inc. (OTC: SBOTF, TSX-V: KLH) (“Stellar”) is pleased to announce that its long-term customer, Neovacs SA - Paris (Paris Alternext: ALNEV), recently reached significant mile...
May 18, 2010
Stellar Biotechnologies, Inc. (OTC: SBOTF, TSX-V: KLH) has appointed Herbert S. Chow, Ph.D., VP: Product Development.
May 11, 2010
Stellar Biotechnologies, Inc. (OTC: SBOTF, TSX-V: KLH) has appointed Dr. Andrew Saxon, a world-renowned expert in human cellular and molecular immunology, Chairman - SAB. Dr. Saxon is Professor & C...
Apr 28, 2010
Stellar Biotechnologies, Inc. (OTC: SBOTF, TSX-V: KLH) has appointed eminent scientist Daniel E. Morse, Ph. D. as Director and Executive VP: Science & Technology effective April 19, 2010.
Apr 14, 2010
CAG Capital Inc. (now Stellar Biotechnologies, Inc.) (OTC: SBOTF, TSX-V: KLH) (the “Company”) is pleased to announce the closing of the acquisition of Stellar Biotechnologies, Inc.